Bladder/Urothelial Cancer
Back To Top
|
| |
| EFC6668 (Age 18 or above) |
| Clinical research coordinator: Daniel Robles - (916) 734-8291 / (916) 762-7251 |
| CCRC: Randomized Study of Larotaxel + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced /Metastatic Urothelial Tract or Bladder Cancer |
| |
| PHII-75 (Age 18 or above) (partial closure) ((VA) Open for severe renal dysfunction patients only.) |
| Clinical research coordinator: Frances Lara - (916) 734-8134 / (916) 762-6282 |
| CCRC: A Phase I/II Study of E7389 Halichondrin B Analog in Metastatic Urothelial Tract Cancer and Renal Insufficiency (NCI #7435) |
| |
| S0337 (Age not specified) |
| Clinical research coordinator: Daniel Robles - (916) 734-8291 / (916) 762-7251 |
| A Phase III Blinded Study of Immediate Post-TURBT Instillation of Gemcitabine Versus Saline in Patients with Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer |
| |
|
Brain Cancer/Metastases
Back To Top
|
| |
| ACNS02B1 (Age up to 21 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Pre-Clinical Pharmacology in Surgical Brain Tumor Specimens |
| |
| ACNS02B3 (Age 1 - 21 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens |
| |
| ACNS0332 (Age varies) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients |
| |
| ANBL00B1 (Age varies) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Neuroblastoma Biology Studies |
| |
| CEPO906A2227 (Age 18 or above) |
| Clinical research coordinator: Karen Schlaier - (916) 734-8814 / (916) 762-9619 |
| An Open-Label, Multi-Center, Phase II Study to Evaluate the Activity of Patupilone (EPO906), in the Treatment of Recurrent or Progressive Brain Metastases in Patients with Non-Small Cell Lung Cancer |
| |
| COG 9346 (Age 6 mos - 21 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Hepatoblastoma Biology Study and Tissue Bank - A Non-Therapeutic Study |
| |
| RTOG 0320 (Age 18 or above) (temporary closure) |
| Clinical research coordinator: Frances Lara - (916) 734-8134 / (916) 762-6282 |
| A Phase III Trial Comparing Whole Brain Radiation and Stereotactic Radiosurgery Alone Versus With Temozolomide or Erlotinib in Patients With Non-Small Cell Lung Cancer and 1-3 Brain Metastases |
| |
| RTOG 0614 (Age 18 or above) |
| Clinical research coordinator: Frances Lara - (916) 734-8134 / (916) 762-6282 |
| CCRC: A Randomized, Phase III, Double-Blind, Placebo-Controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy |
| |
| UCDCC#208 (Age 18 or above) |
| Clinical research coordinator: Barbara Noble - (916) 734-2389 / (916) 762-3778 |
| CCRC: Phase II Study of Bevacizumab (Avastin) and BCNU for Treatment of Relapsed, High Grade Gliomas |
| |
|
Breast Cancer
Back To Top
|
| |
| CALGB 40101 (Age 18 or above) |
| Clinical research coordinator: Karen Schlaier - (916) 734-8814 / (916) 762-9619 |
| CCRC: Cyclophosphamide and Doxorubicin (CA X 4 Cycles) Versus Paclitaxel (4 Cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes: A Phase III Randomized Study |
| |
| CALGB 40302 (Age 18 or above) |
| Clinical research coordinator: Ana Ogilvie - (916) 734-1455 / (916) 762-2435 |
| CIRB: Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant with or without Lapatinib (GW572016) for Postmenopausal Women with Hormone Receptor Positive Advanced Breast Cancer |
| |
| CCSO001 (Age 18 or above) |
| Clinical research coordinator: Steve Martinez - 916-734-8296 |
| Tumescent Mastectomy: A Prospective Comparison to Standard Mastectomy Technique |
| |
| CCSO003 (Age not specified) |
| Clinical research coordinator: - |
| Reducing Extremity Lymphedema through Axillary Lymphatic Preservation (RELAPSE) |
| |
| CZOL446E2352 (Age 18 or above) |
| Clinical research coordinator: Karen Schlaier - (916) 734-8814 / (916) 762-9619 |
| A Prospective, Randomized, Double-Blind, Stratified, Multi-Center, 2-Arm Trial of the Continued Efficacy and Safety of Zometa (Every 4 Weeks vs. Every 12 Weeks) in Patients with Documented Bone Metastases From Breast Cancer |
| |
| D8180C00034 (Age 18 or above) |
| Clinical research coordinator: Karen Schlaier - (916) 734-8814 / (916) 762-9619 |
| A Phase II, Randomised, Open-Label, Pilot Study to Evaluate the Safety and the Effects on Bone Resorption of AZD0530 in Patients with Prostate Cancer or Breast Cancer with Metastatic Bone Disease |
| |
| E1105 (Age 18 or above) |
| Clinical research coordinator: Ana Ogilvie - (916) 734-1455 / (916) 762-2435 |
| CIRB: A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-Line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over-Expressing Metastatic Breast Cancer |
| |
| E5103 (Age 18 or above) |
| Clinical research coordinator: Ana Ogilvie - (916) 734-1455 / (916) 762-2435 |
| CCRC: A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer |
| |
| LPT 111110 (Age 18 or above) |
| Clinical research coordinator: Natasha Perkins - (916) 734-8409 / (916) 762-0819 |
| A Phase II, Single-Arm, Multi-Center Study Evaluating the Combination of Vinorelbine and Lapatinib in Women with ErbB2 Overexpressing Metastatic Breast Cancer |
| |
| MAP.3 (Age 60 or above) |
| Clinical research coordinator: Denise Macias - (916) 734-3219 |
| Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer |
| |
| MAP.3Bone (Age varies) |
| Clinical research coordinator: Denise Macias - (916) 734-3219 |
| Effects of Exemestane on Bone Strength in Postmenopausal Women at Increased Risk of Developing Breast Cancer |
| |
| NEO3-04 (Age 18 or above) |
| Clinical research coordinator: Abby Olusanya - / (916) 762-0511 |
| A Phase IV Study to Evaluate the Long-Term Impact of Identifying Tumor-Draining Lymph Nodes Using Lymphoseek® in Patients with Breast Cancer or Melanoma |
| |
| NSABP B-37 (Age not specified) |
| Clinical research coordinator: Karen Schlaier - (916) 734-8814 / (916) 762-9619 |
| A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Loco-Regional Relapse of Breast Cancer |
| |
| PACCT-1 (Age 18 - 75 yrs) |
| Clinical research coordinator: Ana Ogilvie - (916) 734-1455 / (916) 762-2435 |
| Program for the Assessment of Clinical Cancer Test (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial |
| |
| RTOG 0413/NSABP B-39 (Age 18 or above) (partial closure) |
| Clinical research coordinator: Frances Lara - (916) 734-8134 / (916) 762-6282 |
| A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) For Women With Stage 0, I, or II Breast Cancer |
| |
| S0221 (Age 18 or above) |
| Clinical research coordinator: Ana Ogilvie - (916) 734-1455 / (916) 762-2435 |
| A Phase III Trial of Continuous Schedule AC + G vs. Q2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer |
| |
| S0307 (Age not specified) (VA) |
| Clinical research coordinator: Ana Ogilvie - (916) 734-1455 / (916) 762-2435 |
| CCRC: A Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer |
| |
| S0500 (Age not specified) |
| Clinical research coordinator: Natasha Perkins - (916) 734-8409 / (916) 762-0819 |
| A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment |
| |
| S0622 (Age 18 or above) (VA) |
| Clinical research coordinator: Ana Ogilvie - (916) 734-1455 / (916) 762-2435 |
| CCRC: Phase II Studies of Two Different Schedules of Dasatinib (NSC-732517) in Bone-Metastasis Predominant Metastatic Breast Cancer |
| |
| TOC4129g (Age 18 or above) |
| Clinical research coordinator: Ana Ogilvie - (916) 734-1455 / (916) 762-2435 |
| A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated Her2-Positive Metastatic Breast Cancer |
| |
| UCDCC#186 (Age 18 or above) |
| Clinical research coordinator: Jaclyn Morrison - (916) 734-0162 / (916) 762-4297 |
| Serum Glycan Analysis in Breast Cancer |
| |
|
Colorectal Cancer
Back To Top
|
| |
| |
| CALGB C80405 (Age 18 or above) |
| Clinical research coordinator: Barbara Noble - (916) 734-2389 / (916) 762-3778 |
| CCRC: A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5-FU / Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum |
| |
| Colon |
| CTSU E5202 (Age 18 or above) (temporary closure) |
| Clinical research coordinator: Barbara Noble - (916) 734-2389 / (916) 762-3778 |
| A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers |
| |
| N0147 (Age 18 or above) (partial closure) (Partial closure to patients age 70 and above 10/27/08. ) |
| Clinical research coordinator: Barbara Noble - (916) 734-2389 / (916) 762-3778 |
| CIRB: A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer |
| |
| Rectal |
| ACOSOG Z6041 (Age 18 or above) |
| Clinical research coordinator: Frances Lara - (916) 734-8134 / (916) 762-6282 |
| A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for uT2uN0 Rectal Cancer |
| |
| CTSU NSABP R-04 (Age 18 or above) |
| Clinical research coordinator: Barbara Noble - (916) 734-2389 / (916) 762-3778 |
| CCRC: A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine With or Without Oxaliplatin With Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-Fluorouracil with or without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum |
| |
|
Correlative and Ancillary Studies
Back To Top
|
| |
| AALL05B1 (Age varies) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens |
| |
| AHOD04B1 |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Hodgkin Disease (HD) Banking Study |
| |
| COG 9902 (Age up to 50 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| A Group Wide Protocol for Collecting and Banking Pediatric Cancer Research Specimens - An IRS Protocol |
| |
| GOG 0136 (Age not specified) |
| Clinical research coordinator: Jaclyn Morrison - (916) 734-0162 / (916) 762-4297 |
| Acquisition of Human Gynecologic Specimens and Serum to Be Used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer |
| |
| RTOG 0514 (Age 18 or above) |
| Clinical research coordinator: Frances Lara - (916) 734-8134 / (916) 762-6282 |
| Establishment of a Head and Neck Cancer Tissue/Specimen Bank |
| |
| S0309 (Age not specified) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| Myeloma Specimen Repository Protocol, Ancillary |
| |
| S9245 (Age not specified) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| Central Lymphoma Repository Tissue Procurement Protocol for Relapse or Recurrent Disease, Ancillary |
| |
| S9910 (Age 18 or above) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| Leukemia Centralized Reference Laboratories and Tissue Repositories, Ancillary |
| |
| S9925 (Age 18 or above) (VA) |
| Clinical research coordinator: George Bennig - (916) 734-4913 / (916) 762-4204 |
| CCRC: Ancillary, Lung Cancer Specimen Repository Protocol |
| |
| UCDCC#155 (Age 18 or above) |
| Clinical research coordinator: Jaclyn Morrison - (916) 734-0162 / (916) 762-4297 |
| EGFR Pathway Mutations in Lung Cancer Patient Tumors and Blood |
| |
| UCDCC#183 (Age 18 or above) |
| Clinical research coordinator: Jaclyn Morrison - (916) 734-0162 / (916) 762-4297 |
| Clinical Protocol to Evaluate Glycans Analysis As a Diagnostic Test for Ovarian Cancer |
| |
| UCDCC#186 (Age 18 or above) |
| Clinical research coordinator: Jaclyn Morrison - (916) 734-0162 / (916) 762-4297 |
| Serum Glycan Analysis in Breast Cancer |
| |
|
Endometrial Cancer
Back To Top
|
| |
| PHII-89 (Age 18 or above) |
| Clinical research coordinator: Ana Ogilvie - (916) 734-1455 / (916) 762-2435 |
| CCRC: A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma (NCI 7713; PHL-062) |
| |
|
Head and Neck Cancers
Back To Top
|
| |
| ACNS0331 |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| A Phase III Double Randomized Trial Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy 18.00 Gy and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblastoma |
| |
|
Hodgkin Lymphoma
Back To Top
|
| |
| AHOD0031 (Age up to 21 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| A Phase III Group-Wide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents with Newly Diagnosed Intermediate Risk Hodgkin Disease |
| |
| AHOD04B1 |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Hodgkin Disease (HD) Banking Study |
| |
| PHI-59 (Age 18 or above) |
| Clinical research coordinator: Karen Schlaier - (916) 734-8814 / (916) 762-9619 |
| CCRC: Phase I and Pharmacokinetic Study of Vorinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction (NCI# 8057)(UPCI 07-013) |
| |
| UCDCC#196 (Age 18 or above) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| Reduced Intensity Stem Cell Transplantation (RIST) for Patients with Hematological Malignancies Conditioned with Fludarabine and Busulfan |
| |
|
Kidney Cancer
Back To Top
|
| |
| AREN03B2 (Age 1 - 30 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Renal Tumors Classification, Biology, and Banking Study |
| |
| AREN0532 (Age varies) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Treatment for Very Low, Low and Standard Risk Favorable Histology Wilms Tumor |
| |
| AS1411-C-202 (Age 18 or above) (temporary closure) |
| Clinical research coordinator: Daniel Robles - (916) 734-8291 / (916) 762-7251 |
| A Phase II, Open Label, Single Arm Study of AS1411 in Patients with Metastatic Renal Cell Carcinoma |
| |
| E2804 (Age 18 or above) (VA) |
| Clinical research coordinator: Daniel Robles - (916) 734-8291 / (916) 762-7251 |
| CCRC: The BeST Trial: A Randomized Phase II Study of VEGF, RAF Kinase, and mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma |
| |
| E2805 (Age 18 or above) (temporary closure) |
| Clinical research coordinator: Daniel Robles - (916) 734-8291 / (916) 762-7251 |
| CCRC: ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma |
| |
|
Leukemia
Back To Top
|
| |
| |
| AALL0331 (Age 1 - 9 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Phase III Randomized Study of Different Combination Chemotherapy Regimens in Pediatric Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia |
| |
| AALL03B1 (Age 1 - 22 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Classification of Acute Lymphoblastic Leukemia |
| |
| AALL03N1 (Age up to 21 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Understanding the Ethnic and Racial Differences in Survival in Children with Acute Lymphoblastic Leukemia |
| |
| PHI-57 (Age 18 or above) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| CCRC: Phase I and Pharmacodynamic Study of GTI-2040 (NSC 722929, IND 67368) in Acute Leukemias (NCI #7689) |
| |
| PHII-73 (Age 18 or above) (VA) |
| Clinical research coordinator: Karen Schlaier - (916) 734-8814 / (916) 762-9619 |
| CCRC: A Phase II Study of VEGF Trap (NSC 724770) in Patients with MDS (NCI #7518) |
| |
| S9007 (Age 18 or above) (VA) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| CCRC: Cytogenetic Studies in Leukemia Patients |
| |
| UC Berkeley (Age up to 14 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Molecular Epidemiology Childhood Leukemia |
| |
| UCDCC#196 (Age 18 or above) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| Reduced Intensity Stem Cell Transplantation (RIST) for Patients with Hematological Malignancies Conditioned with Fludarabine and Busulfan |
| |
| ALL |
| AALL0232 (Age 16 - 30 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| High Risk B-Precursor Acute Lymphoblastic Leukemia |
| |
| AALL0434 (Age 1 - 30 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Intensified Methotrexate, Nelarabine (Compound 506U78; IND#52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) |
| |
| CCPO001 (Age up to 18 yrs) |
| Clinical research coordinator: - |
| Development of Leukemia Stem Cell Targeted Therapy in Childhood Leukemia |
| |
| AML |
| AAML0531 (Age up to 29 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg®) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults |
| |
| S0605 (Age 60 or above) (VA) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| CCRC: A Phase II Study of Lenalidomide (Revlimid®) (NSC-703813) for Previously Untreated Non-M3, Deletion 5q Acute Myeloid Leukemia (AML) in Patients Age 60 or Older Who Decline Remission Induction Therapy |
| |
| CLL |
| 152CL201 (Age 18 or above) (VA) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| CCRC: A Randomized, Open-Label, Multicenter, Phase II Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination with Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia |
| |
| CALGB C10501 (Age 18 or above) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| CIRB: A Phase III Intergroup CLL Study of Asymptomatic Patients with Untreated Chronic Lymphocytic Leukemia Randomized to Early Intervention Versus Observation with Later Treatment in the High Risk Genetic Subset with IgVh Unmutated Disease |
| |
|
Liver Cancer
Back To Top
|
| |
| PHII-83 (Age 18 or above) (temporary closure) ((VA) 5/19/09: closed for interim analysis) |
| Clinical research coordinator: Patsy Pasquinelli - (916) 734-5129 / (916) 762-7213 |
| CCRC: A Phase II Trial of Dasatinib (BMS-354825) in Advanced Hepatocellular Carcinoma (NCI #7792) |
| |
|
Lung Cancer
Back To Top
|
| |
| |
| S9925 (Age 18 or above) (VA) |
| Clinical research coordinator: George Bennig - (916) 734-4913 / (916) 762-4204 |
| CCRC: Ancillary, Lung Cancer Specimen Repository Protocol |
| |
| UCDCC#155 (Age 18 or above) |
| Clinical research coordinator: Jaclyn Morrison - (916) 734-0162 / (916) 762-4297 |
| EGFR Pathway Mutations in Lung Cancer Patient Tumors and Blood |
| |
| Non-Small Cell |
| 109493 (Age 18 or above) |
| Clinical research coordinator: Courtney Eddings - (916) 734-3604 / (916) 762-4248 |
| A Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of RecMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Resectable MAGE-A3-Positive Non-Small Cell
Lung Cancer |
| |
| A4021016 (Age 18 or above) |
| Clinical research coordinator: Courtney Eddings - (916) 734-3604 / (916) 762-4248 |
| Randomized, Open Label, Phase III Trial of CP-751,871 Plus Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients with Non-Small Cell Lung-Cancer |
| |
| CALGB 140503 (Age 18 or above) |
| Clinical research coordinator: Courtney Eddings - (916) 734-3604 / (916) 762-4248 |
| A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (<= 2 cm) Peripheral Non-Small Cell Lung Cancer |
| |
| CASA404A2301 (Age 18 or above) |
| Clinical research coordinator: George Bennig - (916) 734-4913 / (916) 762-4204 |
| A Phase III, Randomized, Double-Blind, Placebo-Controlled
Multi-Center Study of ASA404 in Combination with Paclitaxel and Carboplatin as First-Line Treatment for Locally Advanced or Metastatic (Stage IIIb/IV) Non-Small Cell Lung Cancer (NSCLC) |
| |
| CEPO906A2227 (Age 18 or above) |
| Clinical research coordinator: Karen Schlaier - (916) 734-8814 / (916) 762-9619 |
| An Open-Label, Multi-Center, Phase II Study to Evaluate the Activity of Patupilone (EPO906), in the Treatment of Recurrent or Progressive Brain Metastases in Patients with Non-Small Cell Lung Cancer |
| |
| E1505 (Age 18 or above) (VA) |
| Clinical research coordinator: Frances Lara - (916) 734-8134 / (916) 762-6282 |
| CCRC: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC) |
| |
| E5597 (Age 18 or above) |
| Clinical research coordinator: Jaclyn Morrison - (916) 734-0162 / (916) 762-4297 |
| CCRC: A Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non-Small Cell Lung Cancer |
| |
| PHII-57 (Age 18 or above) (VA) |
| Clinical research coordinator: Joan Houston - (916) 734-8381 / (916) 762-9901 |
| CCRC: A Phase II Study of Bortezomib (PS-341) for Patients With Advanced Bronchoalveolar Carcinoma (BAC) (NCI#7003) |
| |
| PHII-74 (Age 18 or above) (Open to taxane sensitive patients only) |
| Clinical research coordinator: Courtney Eddings - (916) 734-3604 / (916) 762-4248 |
| CCRC: A Phase II Study of the Halichondrin B Analog E7389 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Previously Treated with a Taxane (NCI #7437) |
| |
| RTOG 0320 (Age 18 or above) (temporary closure) |
| Clinical research coordinator: Frances Lara - (916) 734-8134 / (916) 762-6282 |
| A Phase III Trial Comparing Whole Brain Radiation and Stereotactic Radiosurgery Alone Versus With Temozolomide or Erlotinib in Patients With Non-Small Cell Lung Cancer and 1-3 Brain Metastases |
| |
| RTOG 0618 (Age 18 or above) |
| Clinical research coordinator: Frances Lara - (916) 734-8134 / (916) 762-6282 |
| A Phase II Trial of Sterotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Operable Stage I/II Non-Small Cell Lung Cancer |
| |
| S0424 (Age 18 or above) (partial closure) (VA and Partial Closure: Smoker Strata closing due to meeting accrual goal.) |
| Clinical research coordinator: Jaclyn Morrison - (916) 734-0162 / (916) 762-4297 |
| CCRC: Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men |
| |
| S0429 (Age 18 or above) |
| Clinical research coordinator: Courtney Eddings - (916) 734-3604 / (916) 762-4248 |
| CCRC: A Pilot (Phase I) Study of Weekly Docetaxel and Cetuximab Chemoradiation for Poor Risk Stage III Non-Small Cell Lung Cancer |
| |
| S0533 (Age 18 or above) (partial closure) (High risk stratum (Stratum 2) is permanently closed to accrual.) |
| Clinical research coordinator: Frances Lara - (916) 734-8134 / (916) 762-6282 |
| CCRC: A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients with Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer |
| |
| S0635 (Age 18 or above) (temporary closure) |
| Clinical research coordinator: Courtney Eddings - (916) 734-3604 / (916) 762-4248 |
| A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma with BAC Features (AdenBAC) |
| |
| S0636 (Age 18 or above) (temporary closure) |
| Clinical research coordinator: George Bennig - (916) 734-4913 / (916) 762-4204 |
| CCRC: A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Never-Smokers with Stage IIIB and IV Primary NSCLC Adenocarcinomas |
| |
| S0720 (Age not specified) |
| Clinical research coordinator: Courtney Eddings - (916) 734-3604 / (916) 762-4248 |
| Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients with Stage I Non-Small Cell Lung Cancer (NSCLC) |
| |
| UCDCC#177 (Age 18 or above) |
| Clinical research coordinator: George Bennig - (916) 734-4913 / (916) 762-4204 |
| A Phase I/II Study of Erlotinib (TARCEVA) and Cetuximab (ERBITUX) in Advanced Solid Tumors with an Emphasis on Non-Small Cell Lung Cancer (NSCLC)(OSI4267s) |
| |
| UCDCC#185 (Age 18 or above) |
| Clinical research coordinator: Natasha Perkins - (916) 734-8409 / (916) 762-0819 |
| A Phase I/II Trial of Abraxane TM ® (ABI-007) and ALIMTA (Pemetrexed) in Advanced Solid Tumors with Emphasis on Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer |
| |
| XL184-202 (Age 18 or above) |
| Clinical research coordinator: Patsy Pasquinelli - (916) 734-5129 / (916) 762-7213 |
| CCRC: A Phase 1/2 Study of XL184 with or without Erlotinib in Subjects with Non-Small Cell Lung Cancer |
| |
| Z4033 (Age varies) |
| Clinical research coordinator: Frances Lara - (916) 734-8134 / (916) 762-6282 |
| A Pilot Study of Radiofrequency Ablation in High-Risk Patients with Stage IA Non-Small Cell Lung Cancer |
| |
| Small Cell |
| CTSU C30610 (Age 18 or above) |
| Clinical research coordinator: Courtney Eddings - (916) 734-3604 / (916) 762-4248 |
| CCRC: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide |
| |
| M06-822 (Age 18 or above) (VA; Phase II open to accrual) |
| Clinical research coordinator: Natasha Perkins - (916) 734-8409 / (916) 762-0819 |
| CCRC: A Phase I/IIA Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies |
| |
| PHII-90 (Age 18 or above) (temporary closure) |
| Clinical research coordinator: Joan Houston - (916) 734-8381 / (916) 762-9901 |
| CCRC: A Phase II Study of AT-101 in Recurrent Extensive Stage Small Cell Lung Cancer (NCI# 8027) |
| |
| UCDCC#214 (Age 18 or above) (temporary closure) |
| Clinical research coordinator: Natasha Perkins - (916) 734-8409 / (916) 762-0819 |
| Phase I Trial of Carboplatin and Etoposide in Combination with Everolimus (RAD001) in Advanced Solid Tumors, with Emphasis on Small Cell Lung Cancer (SCLC) |
| |
|
Melanoma
Back To Top
|
| |
| E1697 (Age varies) |
| Clinical research coordinator: Karen Schlaier - (916) 734-8814 / (916) 762-9619 |
| CCRC: Phase III Randomized Study of Four Weeks High Dose IFN-alpha 2b in Stage T2b No, T3a-b, T4a-b No, and T1-4, N1a, 2a, 3 (microscopic) Melanoma |
| |
| LX01-315 (Age 18 or above) |
| Clinical research coordinator: Karen Schlaier - (916) 734-8814 / (916) 762-9619 |
| A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7 Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma |
| |
| NEO3-04 (Age 18 or above) |
| Clinical research coordinator: Abby Olusanya - / (916) 762-0511 |
| A Phase IV Study to Evaluate the Long-Term Impact of Identifying Tumor-Draining Lymph Nodes Using Lymphoseek® in Patients with Breast Cancer or Melanoma |
| |
| S0438 (Age 18 or above) (temporary closure) ((VA) Temporarily closed for interim analysis 2/15/09) |
| Clinical research coordinator: Karen Schlaier - (916) 734-8814 / (916) 762-9619 |
| CCRC: A Randomized Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772) with Either CCI-779 (Temsirolimus: NSC-683864) or R115777 (Tipifarnib: NSC-702818) in Metastatic Melanoma |
| |
|
Mesothelioma
Back To Top
|
| |
| PHII-65 (Age 18 or above) (VA) |
| Clinical research coordinator: Joan Houston - (916) 734-8381 / (916) 762-9901 |
| CCRC: A Phase II Study of AZD2171 in Patients with Malignant Mesothelioma (NCI #7103) |
| |
|
Miscellaneous
Back To Top
|
| |
| PEP-07-214-01-PEP2 (Age 18 or above) |
| Clinical research coordinator: John Linder - (916) 703-5221 / (916) 762-5708 |
| Latino Palliative Care Cancer Study |
| |
| UCDCC#213 (Age 18 or above) |
| Clinical research coordinator: Courtney Eddings - (916) 734-3604 / (916) 762-4248 |
| Single Agent Sorafenib in Advanced Solid Tumors: Phase II Evaluation of Dose Re-Escalation Following a Dose Reduction (IST000375) |
| |
|
Multiple Myeloma
Back To Top
|
| |
| CALGB 100104 (Age varies) (Study will be permanently closed to accrual of new patients on 7/3/09.) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| A Phase III Randomized, Double-Blind Study of Maintenance Therapy with CC-5013 (NSC # 703813, IND # 70116) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma |
| |
| CZOL446EUS129 |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| Bone Marker Directed Dosing of ZOMETA® (Zoledronic Acid) for the Prevention of Skeletal Complications in Patients with Advanced Multiple Myeloma |
| |
| E1A05 (Age 18 or above) |
| Clinical research coordinator: Karen Schlaier - (916) 734-8814 / (916) 762-9619 |
| Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade®)- Lenalidomide (Revlimid®) - Dexamethasone (VRD) versus Bortezomib (Velcade®) - Dexamethasone (VD) for Patients With Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen |
| |
| S0115 (Age varies) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| A Phase II Trial Evaluating Modified High Dose Melphalan (100 mg/m2) and Autologous Peripheral Blood Stem Cell Supported Transplantation (SCT) for Patients with AL Amyloidosis or High Risk (Greater Than or Equal to Age 70 or Poor Renal Function) Patients with Multiple Myeloma (A BMT Study) |
| |
| S0309 (Age not specified) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| Myeloma Specimen Repository Protocol, Ancillary |
| |
| UCDCC#196 (Age 18 or above) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| Reduced Intensity Stem Cell Transplantation (RIST) for Patients with Hematological Malignancies Conditioned with Fludarabine and Busulfan |
| |
|
Non-Hodgkin's Lymphoma
Back To Top
|
| |
| BMT CTN 0401 (Age 18 - 80 yrs) (Protocol will close to accrual of new patients on 7/17/09.) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| Phase III Rituxan/BEAM vs. Bexxar/BEAM with Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-cell Non-Hodgkin's Lymphoma |
| |
| CALGB 50303 (Age 18 or above) (VA) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| CCRC: Phase III Randomized Study of R-CHOP vs. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas |
| |
| CRAD001N2201 (Age 18 or above) |
| Clinical research coordinator: Karen Schlaier - (916) 734-8814 / (916) 762-9619 |
| An Open-Label, Single-Arm Phase II Study of RAD001 in Patients with Refractory Mantle Cell Lymphoma (EUDRACT 2007-005700-40) |
| |
| PHI-58 (Age 18 or above) (temporary closure) |
| Clinical research coordinator: Karen Schlaier - (916) 734-8814 / (916) 762-9619 |
| CCRC: Phase I Study of GX15-070 (NSC# 729280) and Bortezomib in Aggressive Relapsed/Recurrent Non-Hodgkin's Lymphoma (NCI #7943) |
| |
| PHI-59 (Age 18 or above) |
| Clinical research coordinator: Karen Schlaier - (916) 734-8814 / (916) 762-9619 |
| CCRC: Phase I and Pharmacokinetic Study of Vorinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction (NCI# 8057)(UPCI 07-013) |
| |
| S0528 (Age 18 or above) (temporary closure) |
| Clinical research coordinator: Natasha Perkins - (916) 734-8409 / (916) 762-0819 |
| CCRC: A Phase I Study Evaluating the Combination of Lapatinib (GW572016; NSC-727989; IND-75,093) and Everolimus (RAD001; NSC-733504; IND-75,093) in Patients with Advanced Solid Tumors |
| |
| UCDCC#196 (Age 18 or above) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| Reduced Intensity Stem Cell Transplantation (RIST) for Patients with Hematological Malignancies Conditioned with Fludarabine and Busulfan |
| |
| UCDCC#197 (Age 18 or above) (VA) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| CCRC: A Phase II Trial of the Combination of Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular NHL (RV 0163) |
| |
|
Ovarian/Peritoneal Cancer
Back To Top
|
| |
| 20070182 (Age 18 or above) |
| Clinical research coordinator: Karen Schlaier - (916) 734-8814 / (916) 762-9619 |
| CCRC: A Phase Ib Study of AMG 386 in Combination with Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects with Advanced Recurrent Epithelial Ovarian Cancer |
| |
| UCDCC#183 (Age 18 or above) |
| Clinical research coordinator: Jaclyn Morrison - (916) 734-0162 / (916) 762-4297 |
| Clinical Protocol to Evaluate Glycans Analysis As a Diagnostic Test for Ovarian Cancer |
| |
|
Phase I
Back To Top
|
| |
| PHI-53 (Age 18 or above) |
| Clinical research coordinator: Joan Houston - (916) 734-8381 / (916) 762-9901 |
| CCRC: A Phase I Trial of PXD101 in Combination with 13-cis-Retinoic Acid in Advanced Solid Tumor Malignancies (NCI#7251) |
| |
| PHI-54 (Age 18 or above) |
| Clinical research coordinator: Ana Ogilvie - (916) 734-1455 / (916) 762-2435 |
| CCRC: A Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients with Malignant Solid Tumors (NCI#7540) |
| |
| PHI-55 (Age 18 or above) |
| Clinical research coordinator: George Bennig - (916) 734-4913 / (916) 762-4204 |
| CCRC: A Phase I Study of Halichondrin B Analog (E7389) in Combination with Cisplatin in Advanced Solid Tumors (NCI#7427) |
| |
| PHI-59 (Age 18 or above) |
| Clinical research coordinator: Karen Schlaier - (916) 734-8814 / (916) 762-9619 |
| CCRC: Phase I and Pharmacokinetic Study of Vorinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction (NCI# 8057)(UPCI 07-013) |
| |
| PHI-61 (Age 18 or above) |
| Clinical research coordinator: George Bennig - (916) 734-4913 / (916) 762-4204 |
| CCRC: A Phase I Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Advanced Solid Malignancies (NCI #7967) |
| |
| S0528 (Age 18 or above) (temporary closure) |
| Clinical research coordinator: Natasha Perkins - (916) 734-8409 / (916) 762-0819 |
| CCRC: A Phase I Study Evaluating the Combination of Lapatinib (GW572016; NSC-727989; IND-75,093) and Everolimus (RAD001; NSC-733504; IND-75,093) in Patients with Advanced Solid Tumors |
| |
| UCDCC#214 (Age 18 or above) (temporary closure) |
| Clinical research coordinator: Natasha Perkins - (916) 734-8409 / (916) 762-0819 |
| Phase I Trial of Carboplatin and Etoposide in Combination with Everolimus (RAD001) in Advanced Solid Tumors, with Emphasis on Small Cell Lung Cancer (SCLC) |
| |
|
Prostate Cancer
Back To Top
|
| |
| CALGB 90203 (Age 18 or above) |
| Clinical research coordinator: Daniel Robles - (916) 734-8291 / (916) 762-7251 |
| CCRC: A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer |
| |
| D8180C00034 (Age 18 or above) |
| Clinical research coordinator: Karen Schlaier - (916) 734-8814 / (916) 762-9619 |
| A Phase II, Randomised, Open-Label, Pilot Study to Evaluate the Safety and the Effects on Bone Resorption of AZD0530 in Patients with Prostate Cancer or Breast Cancer with Metastatic Bone Disease |
| |
| E3805 (Age 18 or above) |
| Clinical research coordinator: Barbara Noble - (916) 734-2389 / (916) 762-3778 |
| CCRC: CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer |
| |
| PHII-84 (Age 18 or above) (temporary closure) (VA) |
| Clinical research coordinator: Barbara Noble - (916) 734-2389 / (916) 762-3778 |
| CCRC: A Randomized, Phase II Study of GW786034 (Pazopanib) in Stage D0 Relapsed Androgen Sensitive Prostate Cancer Following Limited GnRH Agonist Therapy (NCI #7659) |
| |
| RTOG 0415 (Age 18 or above) |
| Clinical research coordinator: Frances Lara - (916) 734-8134 / (916) 762-6282 |
| CIRB: A Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT Versus Conventionally Fractionated 3D-CRT/IMRT in Patients with Favorable Risk Prostate Cancer |
| |
| RTOG 0521 (Age 18 or above) |
| Clinical research coordinator: Frances Lara - (916) 734-8134 / (916) 762-6282 |
| CIRB: A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMART vs. Androgen Suppression (AS) and 3DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk Prostate Cancer |
| |
| S0421 (Age not specified) (VA) |
| Clinical research coordinator: Daniel Robles - (916) 734-8291 / (916) 762-7251 |
| CCRC: A Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer |
| |
| UCDCC#215 (Age 18 or above) |
| Clinical research coordinator: Patsy Pasquinelli - (916) 734-5129 / (916) 762-7213 |
| Randomized Phase II Trial of Bicalutamide +/- RAD001 in Patients with Hormone-Independent Prostatic Adenocarcinoma (HIPC) After the First-Line Androgen Deprivation Therapy |
| |
| UCDCC#218 (Age varies) |
| Clinical research coordinator: Ana Ogilvie - (916) 734-1455 / (916) 762-2435 |
| CCRC: Assessing PSA Rsponse in Low Dose Ketoconazole in Castration Resistant Prostate Cancer Patients Who Have Failed at Least One Prior Systemic Chemotherapy Regimen |
| |
|
Sarcoma
Back To Top
|
| |
| ANBL00P2 (Age up to 12 mos) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Perinatal Neuroblastoma: Expectant Observation. A Children's Oncology Group Pilot Study |
| |
| AOST0331 (Age 5 - 40 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| A Randomized Trial of the European and American Osteosarcoma Study Group to Optimized Treatment Strategies for Resectable Osteosarcoma Base on Histological Response to Pre-Operative Chemotherapy |
| |
| AP23573-07-302 (Age varies) |
| Clinical research coordinator: Karen Schlaier - (916) 734-8814 / (916) 762-9619 |
| A Pivotal Trial to Determine the Efficacy and Safety of AP23573 when Administered as Maintenance Therapy to Patients with Metastatic Soft-Tissue or Bone Sarcomas |
| |
| ARST0331 (Age up to 49 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Vincristine, Dactinomycin and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma |
| |
| ARST0531 (Age up to 50 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS) |
| |
| PHII-66 (Age 18 or above) |
| Clinical research coordinator: Joan Houston - (916) 734-8381 / (916) 762-9901 |
| A Phase II Study of Bay 43-9006 for Patient with Imatinib and Sunitinib-Resistant Malignant Gastrointestinal Stromal Tumor (NCI #7028) |
| |
| PHII-80 (Age 18 or above) |
| Clinical research coordinator: Joan Houston - (916) 734-8381 / (916) 762-9901 |
| A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas (NCI#7502)(ARD6836) |
| |
| UCDCC#216 (Age 18 or above) |
| Clinical research coordinator: Abby Olusanya - / (916) 762-0511 |
| CCRC: Phase I/II Trial of Neoadjuvant Conformal Radiotherapy plus Sorafenib for Patients with Soft Tissue Sarcoma of the Extremity and Body Wall (IST000449) |
| |
|
Supportive Care and Other
Back To Top
|
| |
| RTOG 0433 (Age 18 or above) |
| Clinical research coordinator: Frances Lara - (916) 734-8134 / (916) 762-6282 |
| A Phase III International Randomized Trial of Single vs. Multiple Fractions for Re-Irradiation of Painful Bone Metastases |
| |
|
Uterine Cancer
Back To Top
|
| |
| PHII-80 (Age 18 or above) |
| Clinical research coordinator: Joan Houston - (916) 734-8381 / (916) 762-9901 |
| A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas (NCI#7502)(ARD6836) |
| |
| PHII-89 (Age 18 or above) |
| Clinical research coordinator: Ana Ogilvie - (916) 734-1455 / (916) 762-2435 |
| CCRC: A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma (NCI 7713; PHL-062) |
| |